Of note, oncogenic mutations in calreticulin (CALR), which aberrantly activate TPO-signaling are the second most frequent driver of MPN after JAK2-V617F are particularly associated with sensitivity to BET- and HDAC-inhibitors [200]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.